<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00034632</url>
  </required_header>
  <id_info>
    <org_study_id>P02095</org_study_id>
    <nct_id>NCT00034632</nct_id>
  </id_info>
  <brief_title>Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P02095)</brief_title>
  <official_title>Open Label, Treatment Protocol for the Safety and Efficacy of Posaconazole (SCH 56592) in the Treatment of Invasive Fungal Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety, tolerance and efficacy of Posaconazole (SCH&#xD;
      56592) under an open label, treatment protocol for subjects with invasive fungal infections:&#xD;
&#xD;
      A. which are refractory or resistant to standard antifungal therapies; B. for which there are&#xD;
      currently no effective therapies; C. with a prior history of serious, severe or&#xD;
      life-threatening toxicities while receiving antifungal therapy; D. with pre-existing organ&#xD;
      dysfunction which precludes the administration of standard antifungal therapies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current clinical trial is designed to provide posaconazole (SCH 56592 to subjects with&#xD;
      invasive fungal infections a) which are refractory or resistant to standard antifungal&#xD;
      therapies or b) for which there are currently no effective therapies. Subjects with such&#xD;
      invasive fungal infections cannot be enrolled in controlled, randomized clinical trials.&#xD;
      Secondly, this clinical trial is also designed to provide posaconazole (SCH 56592) to&#xD;
      subjects with invasive fungal infections who c) have experienced serious or severe toxicities&#xD;
      while receiving standard antifungal therapies or d) have pre-existing organ dysfunction such&#xD;
      as renal dysfunction who require standard antifungal therapy which is precluded because of&#xD;
      the toxicities associated with such therapy. This clinical trial also serves to allow&#xD;
      collection of preliminary data regarding the safety and efficacy of posaconazole (SCH 56592)&#xD;
      against a variety of invasive fungal infections which although serious and life-threatening&#xD;
      are sufficiently rare so that they cannot be studied in a controlled, randomized clinical&#xD;
      trial.&#xD;
&#xD;
      This is an open-label, treatment protocol for a multi-center study of posaconazole (SCH&#xD;
      56592) 200mg orally four times daily (QID) while hospitalized followed by posaconazole (SCH&#xD;
      56592) 400mg orally twice daily (BID) on discharge from hospital, in the treatment of&#xD;
      invasive fungal infections. Approximately 320 subjects have been enrolled at 160 clinical&#xD;
      study centers in the US and worldwide.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2001</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Mycoses</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Posaconazole oral suspension</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Proven or probable invasive fungal infections according to EORTC/MSG criteria.&#xD;
&#xD;
          -  IFI are documented to be refractory to standard antifungal therapy OR intolerant to&#xD;
             standard therapy.&#xD;
&#xD;
          -  Able to take oral medication or take medication via enteral feeding tube.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of serious or severe hypersensitivity or idiosyncratic reactions to azole&#xD;
             antifungals.&#xD;
&#xD;
          -  Concurrent progressive neurological disease (except if due to invasive fungal&#xD;
             infection)&#xD;
&#xD;
          -  Use of medications that are known to interact with azoles and that may lead to&#xD;
             life-threatening side effects: terfenadine, cisapride, ebastine at entry or within 24&#xD;
             hours prior to therapy, or astemizole at entry or within 10 days prior to&#xD;
             entry.concentration/efficacy of azole antifungals: rifampin, carbamazepine.&#xD;
&#xD;
          -  Females pregnant or nursing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Costa Rica</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Saudi Arabia</country>
    <country>Slovenia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Mezhir JJ, Mullane KM, Zarling J, Satoskar R, Pai RK, Roggin KK. Successful nonoperative management of gastrointestinal mucormycosis: novel therapy for invasive disease. Surg Infect (Larchmt). 2009 Oct;10(5):447-51. doi: 10.1089/sur.2008.049. Review.</citation>
    <PMID>19485785</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>May 1, 2002</study_first_submitted>
  <study_first_submitted_qc>May 1, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2002</study_first_posted>
  <last_update_submitted>March 7, 2017</last_update_submitted>
  <last_update_submitted_qc>March 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aspergillosis, Candidiasis, Cryptococcosis, Phaeohyphomycosis</keyword>
  <keyword>Invasive Fungal Infections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Invasive Fungal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Posaconazole</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/policies-perspectives.html</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

